In The Lancet Infectious Diseases, Jean-Michel Molina
and colleagues9 report results of a multicentre, phase 3,
non-inferiority, randomised trial. They measured the
effi cacy and safety of once-daily ritonavir-boosted
elvitegravir compared with twice-daily raltegravir
in treatment-experienced adults infected with
HIV-1.